Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved injectable medications revolutionizing weight management. Both belong to the incretin mimetic drug class but differ in their mechanisms ...

Eli Lilly’s Zepbound bested Novo Nordisk’s Wegovy in the first head-to-head trial comparing weight loss outcomes for people with obesity or overweight, according to top-line results shared by Lilly ...

Childhood obesity rates continue to rise in the U.S., affecting nearly 1 in 5 kids and adolescents ages 2 to 19. To combat it, experts are calling for early and intensive treatment. For some children, ...

The first two years of life are critical for children’s development and growth. While pediatric caregivers rely on a healthy weight trajectory that promotes cognitive, motor and socioemotional skills, ...